Publications by authors named "Ursula A Matulonis"

Claim this Profile
O
Ovarian Sex Cord Tumor With Annular Tubules (SCTAT) Harbor Recurrent Copy Number Alterations, Including Monosomy 22.
Andrew M Leader, Alexander Neil, Stephanie Siegmund, Amir Dehghani, Azra Ligon, Ursula A Matulonis

Mod Pathol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.
Panagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, Tien V Le, Susana Campos, Ursula A Matulonis

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of Tumor Budding as a Prognostic Factor in Ovarian Clear Cell Carcinoma Using an Independent Cohort.
Lawrence H Lin, Lina Irshaid, Ursula A Matulonis, David L Kolin

Int J Gynecol Pathol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the glucocorticoid receptor as a therapeutic strategy for ovarian cancer: The ROSELLA study.
Taliya Lantsman, Ursula A Matulonis

Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.
Elizabeth H Stover, Elizabeth K Lee, Geoffrey I Shapiro, Joan S Brugge, Ursula A Matulonis

Gynecol Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without Mutation.
Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer, Jung Yun Lee, Lydia Gaba, Ursula A Matulonis

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.
Ursula A Matulonis, Ignace Vergote, Kathleen N Moore, Lainie P Martin, Cesar M Castro

Gynecol Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tamoxifen induces PI3K activation in uterine cancer.
Kirsten Kübler, Agostina Nardone, Shankara Anand, Daniel Gurevich, Jianjiong Gao, Ursula A Matulonis

Nat Genet· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smartphone-Based Measures as Indicators of Functional Status in Patients With Advanced Cancer.
Marcin Straczkiewicz, Nancy L Keating, Stephanie M Schonholz, Ursula A Matulonis, Neil Horowitz

JAMA Netw Open· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma.
Stephanie Cham, Niya Xiong, Nabihah Tayob, Carolyn Krasner, Alexi A Wright, Ursula A Matulonis

Gynecol Oncol Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.
Elizabeth K Lee, Niya Xiong, Carolyn Krasner, Madeline Polak, Susana Campos, Ursula A Matulonis

Gynecol Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update on PARP inhibitors for the treatment of ovarian cancer.
Joyce Liu, Ursula A Matulonis

Clin Adv Hematol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ovarian Cancer Therapy.
Diana Miao, Ursula A Matulonis, Rebecca L Porter

Cold Spring Harb Perspect Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma.
Zelei Yang, Saie Mogre, Hyeji Jun, Ruiyang He, Sneha Ghosh Chaudhary, Ursula A Matulonis

Cancer Res Commun· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcoma.
Kevin Tyan, Kevin X Liu, Alicia C Smart, Colleen M Feltmate, Neil S Horowitz, Ursula A Matulonis

Gynecol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers.
Elizabeth K Lee, David L Kolin, Ursula A Matulonis, Britt K Erickson

Gynecol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
Ursula A Matulonis, Jørn Herrstedt, Amit Oza, Sven Mahner, Andrés Redondo

Gynecol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer.
Panagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, Carolyn Krasner, Susana M Campos, Ursula A Matulonis

JCO Precis Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pervasive impact of frailty on ovarian cancer care and the role of prehabilitation: Qualitative perspectives of key stakeholders.
Stephanie Cham, Rachel A Pozzar, Neil Horowitz, Colleen Feltmate, Ursula A Matulonis

J Geriatr Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usability, Acceptability, and Barriers to Implementation of a Collaborative Agenda-Setting Intervention (CASI) to Promote Person-Centered Ovarian Cancer Care: Development Study.
Rachel A Pozzar, James A Tulsky, Donna L Berry, Jeidy Batista, Paige Barwick, Ursula A Matulonis

JMIR Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
Giorgio Bogani, Kathleen N Moore, Isabelle Ray-Coquard, Domenica Lorusso, Ursula A Matulonis

Gynecol Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smartphone-based measures as real-world indicators of functional status in advanced cancer patients.
Marcin Straczkiewicz, Nancy L Keating, Stephanie M Schonholz, Ursula A Matulonis, Neil Horowitz

medRxiv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Kathleen N Moore, Domenica Lorusso, Ana Oaknin, Amit Oza, Nicoletta Colombo, Ursula A Matulonis

Gynecol Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Tumors.
Louise Cadzow, Jehrod Brenneman, Erica Tobin, Pamela Sullivan, Sumeet Nayak, Ursula A Matulonis

Cancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer.
Mubin Tarannum, Khanhlinh Dinh, Juliana Vergara, Grace Birch, Yasmin Z Abdulhamid, Ursula A Matulonis

Sci Adv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis